

Figure 1




Figure 3

306




Figure 4

306




Figure 5

300
v

TVC Event/VSM Matrix™ 302

For Scenarios

Assumptions and Events
grouped into Scenarios 304




Figure 6

Fig 244

Stakeholders Example




Figure 7

Fig 234

Capabilities Example




Figure 8

Fig 236

Infrastructure Example




Figure 9

Fig 238

Network Example




Figure 10




Figure 11

005090" 22498560

4100




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16

Calculation of Outcome Variance

PV of Bio-tech drug projects	468.999
PV of Bio-informatics tools	134.424
Free cash PV	2.649
Current PV of GreenGene	600.774
Last year's PV	471.418
Delta_PV	129.356
COCr on last yr PV	75.427
Outcome Variance	53.929

Analysis of Outcome Variance

cause	effect \$ mlns
revised projection tool #4 sales	
from 0.007% to 0.015%	25.009
world bio-tech sales growth thru 2005	
from 11.5% to 12.5%	14.931
revised projection drug #26 sales	
from 0.45% to 0.70%	10.196
last yr wrld sales grew 12.9% not 11.5%	7.000
increased R&D spending last year	-1.607
increased future R&D spending	-1.461
effect of WHO donation	-0.306
last yr's investment income better	0.167
	53.929

Figure 17




Figure 18

Fig 225

Stakeholder Stored Assumptions

At time t_i		TVC Event/VSM Matrix™		Stakeholder Reference		Stakeholder Reference		Stakeholder Reference	
Event View									
Related Assumptions	Events	Event 1	Management	Event 2	Management	Event 3	User A	etc.	
		Assumption a	Management	Assumption b	Management	Assumption e	User A		
		Assumption a	User B	Assumption c	Management	Assumption e	User B		
		Assumption a	User C	Assumption d	Management				

Figure 19




Figure 20




Figure 21

Fig 227

Stakeholder Interactivity - Calculations




Figure 22